The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


GlaxoSmithKline Biologicals S.A.EU/1/09/578/001

Main Information

Trade NameAdjupanrix
Active SubstancesPurified antigen fractions of inactivated split virions a/vietnam/1194/2004 nibrg-14 (h5n1)
Dosage FormEmulsion and suspension for emulsion for injection
Licence HolderGlaxoSmithKline Biologicals S.A.
Licence NumberEU/1/09/578/001

Group Information

ATC CodeJ07BB Influenza vaccines
J07BB02 influenza, inactivated, split virus or surface antigen


License statusAuthorised
Licence Issued05/11/2009
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back